Miridesap is an antineoplastic which depletes circulating serum amyloid P component (SAP) almost completely but leaves some SAP in amyloid deposits for specific recognition by subsequently administered therapeutic anti-SAP antibodies.
We use some essential cookies to make this website work. These cookies aren't used to track you. We'd
like
to set additional cookies to understand how you use our website. This information is used to improve
our
services.